Evidence map›Paper›PMID 35433411›Full record

ArticleFrontiers in oncology2022

Effective Systemic Treatment of Choroidal Metastases NSCLC With Surgery After Crizotinib: A Case Report.

Shilan Liu, Xiao Liu, Ting Wang, Chunhua Zeng, Baichen Ren, Xiaodan Yu, Min Xu, Wenjuan Li, Zhihui Qiao, Chuanyun You and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Control of Intraocular Metastases ofCase reports in oncology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Shilan LiuDepartment of Respiratory and Critical Care Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
Xiao LiuDepartment of Respiratory and Critical Care Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
Ting WangLung Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
Chunhua ZengDepartment of Respiratory and Critical Care Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
Baichen RenDepartment of Respiratory and Critical Care Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
Xiaodan YuDepartment of Respiratory and Critical Care Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
Min XuDepartment of Respiratory and Critical Care Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
Wenjuan LiDepartment of Respiratory and Critical Care Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
Zhihui QiaoDepartment of Respiratory and Critical Care Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
Chuanyun YouDepartment of Respiratory and Critical Care Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
Qinghui YangDepartment of Respiratory and Critical Care Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
Mei ChenDepartment of Respiratory and Critical Care Medicine, Chengdu Fifth People's Hospital, Chengdu, China.
Chengdu Fifth People's Hospital · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Choroidal metastasis as an initial presenting feature of lung cancer with EML4-ALK translocation is exceedingly rare and greatly impacts patient quality of life (QOL). There are no recommended treatments for such patients, and palliative care remains limited. It is unclear whether surgical resection of primary pulmonary lesions, systemic antitumor therapy, targeted therapy, or localized ocular therapy are effective in treating choroidal metastases in EML4-ALK rearranged oligometastatic non-small cell lung cancer (NSCLC). Here, we present the case of choroidal metastases secondary to lung cancer and EML4-ALK translocation in a 57-year-old woman who firstly underwent resection of lung lesions followed by oral administration of crizotinib without local treatment or systemic chemotherapy. Since then she had a rapid and complete response to crizotinib with 27 months of progression-free survival.

Indexed as

choroidal metastasiscrizotinibEML4-ALK translocationnon-small cell lung carcinomaoligometastasessurgery

Identifiers

PMID35433411
PMCPMC9009287
OpenAlexW4220772456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.